Etanercept in Hidradenitis Suppurativa
Hidradenitis Suppurativa
About this trial
This is an interventional treatment trial for Hidradenitis Suppurativa focused on measuring Hidradenitis suppurativa, etanercept
Eligibility Criteria
Inclusion Criteria: Definitive diagnosis of hidradenitis suppurativa Age > 16 years No presence of infections other then hidradenitis suppurativa. Disease activity index > 20 Signed informed consent Exclusion Criteria: Received any live (attenuated) vaccines within 4 weeks of enrolment visits Has a history of anti-cardiolipin antibodies associated with a thrombotic event Has a history of confirmed blood dyscrasias Has a significant active infection or any underlying diseases that could predispose subjects to infections (ie. Advanced or poorly controlled diabetes). Demonstrates liver function abnormality [SCOT, SGPT>2 X upper limit of normal] Has significant concurrent medical diseases including cancer or a history of cancer (other than resected cutaneous basal and squamous cell carcinoma) within 5 years of entering the enrollement period incompensated congestive heart failure, myocardial infarction within 12 months, unstable angina pectoris, uncontrolled hypertension, severe pulmonary disease, history of HIV infection, or central nervous system demyelinating events suggestive of multiple sclerosis. Has a history of known liver cirrhosis, fibrosis or fatty liver Has a history of any viral hepatitis Has renal disease (creatinine level > 175μmol/L) Has leucopenia (WBC <3500 x 106 /L) Has Thrombocytopenia (PLT's < 125 x 109 /L) Is pregnant or breast feeding.
Sites / Locations
- 4th Department of Internal Medicine, University of Athens, Medical School